Afuco™ Anti-CTLA4 ADCC Recombinant Antibody (Ipilimumab), ADCC Enhanced (CAT#: AFC-TAB-067)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CTLA4. Ipilimumab (known as MDX-010 and MDX-101), marketed as Yervoy, is a drug used for the treatment of melanoma, a type of skin cancer. It is a U.S. Food and Drug Administration (FDA) approved human monoclonal antibody, and works by activating the immune system by targeting CTLA-4.
Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism that interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy cancer cells.
Specific Inquiry
RNA Expression
Figure 1 RNA cell line category: Cell line enhanced (Karpas-707, SK-MEL-30, U-266/70, U-266/84)
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000163599-CTLA4
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000163599-CTLA4
Figure 1 RNA cell line category: Cell line enhanced (Karpas-707, SK-MEL-30, U-266/70, U-266/84)
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000163599-CTLA4
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000163599-CTLA4
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Human
- Type
- ADCC enhanced antibody
- Species Reactivity
- Human
- Clone
- Ipilimumab
- Applications
- FuncS, IF, Neut, ELISA, FC
- Conjugate
- Unconjugated
- Trade name
- Yervoy
- Generic Name
- Ipilimumab
- Related Disease
- Melanoma, metastatic
Product Property
- Purity
- >95% by SDS-PAGE
- Storage
- Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- Ipilimumab; yervoy; 477202-00-9; MDX-010; MDX-101; Yervoy; MDX-010; MDX-101; CTLA4; cytotoxic T-lymphocyte-associated protein 4; celiac disease 3, CELIAC3; cytotoxic T-lymphocyte protein 4; CD; CD28; CD152; GSE; ICOS; CD152 isoform; celiac disease 3;
- Gene ID
- 1493
- UniProt ID
- P16410
Related Resources
Rheumatoid Arthritis
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Ipilimumab"
Anti-Human CTLA4 Recombinant Antibody (Ipilimumab)Recombinant monoclonal antibody to CTLA4. Ipilimumab (known as MDX-010 and MDX-101), marketed as Yervoy, is a drug used for the treatment of melanoma, a type of skin cancer. It is a U.S. Food and Drug Administration (FDA) approved human monoclonal antibody, and works by activating the immune system by targeting CTLA-4.
Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism that interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy cancer cells.
See other products for "CTLA4"
Select a product category from the dropdown menu below to view related products.
Please select product type
Human Antibody
Immunotoxin
Rat Antibody
Chimeric Antibody
Mouse Antibody
Humanized Antibody
Recombinant Antibody
Neutralizing Antibody
Blocking Antibody
Rabbit Monoclonal Antibody
scFv Fragment Antibody
Fab Fragment Antibody
ADCC Enhanced Antibody
Single-domain Antibody
Agonistic Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-067 | Anti-Human CTLA4 Recombinant Antibody (Ipilimumab) | WB, FuncS, IF, Neut, ELISA, FC, IP | IgG1 - kappa |
| TAB-206 | Anti-Human CTLA4 Recombinant Antibody (Ticilimumab (Tremelimumab)) | WB, IF, IP, Neut, FuncS, ELISA, FC | IgG2 |
Customer Reviews and Q&As
Customer Review
Q&As
-
Stable Storage
Once reconstituted, the antibody remains stable and functional for a good period. This has been very convenient for our long-term projects. -
User-Friendly
From ordering to actual use in the lab, the whole experience has been smooth. The antibody is easy to handle, and the results speak for themselves. -
Detailed Documentation
The documentation provided with this antibody is detailed and helpful. Instructions for dilutions and usage guidelines have made our process much more straightforward.
Popular products with customers
Application: WB, IP, IF, FuncS, FC, Neut, ELISA
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: FuncS, IF, Neut, ELISA, FC, IP, ICC
Application: WB, Neut, FuncS
Application: WB, IF, FuncS
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: FC, IA, IF, IP, IHC, FuncS
Application: Neut, IHC, Activ, FuncS, IF, ELISA
-1.png)
Application: ELISA, WB
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
